Netherlands· NL-ac6b388a2886
Adtralza 300 mg, oplossing voor injectie in voorgevulde pen
A tralokinumab product containing tralokinumab, registered in Netherlands by LEO Pharma A/S. The same ATC class is registered in 14 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Tralokinumab is registered in 14 of 19 countries.
Countries holding a registration under ATC D11AH07 (tralokinumab), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 8 of them publish a price we can compare per daily dose
Tralokinumab · ATC D11AH07
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tralokinumab costs, country by country.
Normalised to the WHO defined daily dose (16.1 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tralokinumab · price per daily dose (16.1 mg)
USD · FX 28 Sept 2026
- CH Switzerland$34.49
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- TRALOKINUMAB
- Manufacturer
- LEO Pharma A/S
- Country
- Netherlands (NL)
- ATC code
- D11AH07
- ATC class
- Tralokinumab
- Defined daily dose
- 16.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/21/1554
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tralokinumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceADTRALZA 300 mg, solution injectable en stylo prérempliLEO PHARMACEUTICAL PRODUCTS (DANEMARK)
- IrelandAdtralza 300 mg solution for injection in pre-filled penLEO Pharma A/S
- CzechiaADTRALZALEO Pharma A/S, Ballerup
- CanadaADTRALZALEO PHARMA INC
- SwitzerlandAdtralza
- SpainADTRALZA 150 mg SOLUCION INYECTABLE EN JERINGA PRECARGADALeo Pharma A/S
- FinlandAdtralzaLeo Pharma A/S
- United KingdomAdtralza 150mg/1ml solution for injection pre-filled syringesLEO Pharma
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Adtralza
- Iceland · Adtralza
- Liechtenstein · Adtralza
- Norway · Adtralza
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1fad1cbf-36b7-40ad-b083-b49286df0915 GET /v1/drugs/1fad1cbf-36b7-40ad-b083-b49286df0915?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor injectie",
"route": "Subcutaan gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/adtralza-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Tralokinumab",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp130778",
"excipients": [
"AZIJNZUUR (E 260), GECONCENTREERD",
"NATRIUMACETAAT 3-WATER (E 262)",
"NATRIUMCHLORIDE",
"POLYSORBAAT 80 (E 433)",
"WATER VOOR INJECTIE"
],
"substances": [
"TRALOKINUMAB"
],
"leaflet_url": null,
"authorised_at": "2021/06/17",
"procedure_number": "EMEA/H/C/005255",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/21/1554",
"additional_monitoring": "N"
}See everything about tralokinumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.